Cardiac Amyloidosis

With the first drug treatments for cardiac amyloidosis recently entering the market, there has been an explosion of interest to diagnose and care for these patients. It is considered a rare disease, but many experts now say it is actually just be under diagnosed. The disease is caused by protein misfolding. Normally soluble proteins in the bloodstream become insoluble and deposit abnormally in the tissues and organs throughout the body. There are three main kinds of amyloid that affect the heart, light chain amyloid (AL) and two types of transthyretin amyloid (ATTR or TTR). The first type of ATTR is hereditary, or familial amyloid, and the second is wild type, or age-related TTR amyloid. Nuclear imaging, echocardiography, CT and MRI all play roles in diagnosing amyloid and in determining the subtype, which is required for targeted treatment. 

Roberto Lang, MD, explained the AI advances in echocardiography that will make it a requirement to have in the coming years at ASE 2023. #ASE #AIhealthcare #ASE2023

Echo labs not using AI will be left behind

Echocardiography expert Roberto Lang, MD, says artificial intelligence will be so important to cardiac ultrasound in the near future that echo labs not using it will be inefficient and less accurate than labs that do use it.

artificial intelligence robot evaluates healthcare data

FDA grants breakthrough designation for new AI model to detect cardiac amyloidosis in ECG results

Anumana, Pfizer and Mayo Clinic all worked together to develop the advanced algorithm. The groups are now targeting full regulatory approval in the U.S., Europe and Japan.

Thumbnail

‘A hugely significant development’: Severe heart condition reverses in 3 patients, shocking experts

Cardiologists and other physicians have always believed cardiac transthyretin amyloidosis, a progressive heart condition associated with a high mortality rate, was irreversible. Now, though, new evidence suggests that there may be hope. 

VIDEO: American Society of Nuclear Cardiology (ASNC) President Mouaz Al-Mallah, MD, chair of cardiovascular PET and associate director of nuclear cardiology, Houston Methodist DeBakey Heart and Vascular Center, and ASNC President-elect Larry Phillips, MD, director of nuclear cardiology, NYU Langone, outline the new technologies available and why upgrading cardiac nuclear labs matters and what is the ROI. #ASNC

What is the ROI for upgrading nuclear cardiology labs?

Some nuclear cardiology labs are still using SPECT systems that are 20-25 years old. Is it time to make an upgrade? 

cardiac amyloidosis on bone scan

Cardiac amyloidosis becoming less rare thanks to nuclear medicine studies

A new study in the Journal of Nuclear Medicine offers insight into how the condition affects the general population, as well as how radiologists can help in the cardiac amyloidosis diagnostic journey.

Thumbnail

AI specialists ink deal with Pfizer to target cardiac amyloidosis

Cardiac amyloidosis can be especially challenging to identify and diagnose, making it a perfect target for advanced AI models.

Late-breaking cardiovascular study presentation at AHA 2022. #AHA22

VIDEO: Key takeaways from AHA 2022

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

Thumbnail

Amyloidosis patients can safely undergo TAVR

Researchers focused on 30-day outcomes, sharing their findings in the American Journal of Cardiology.

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.